Skip to Content
Global News Select

Angle's Parsortix System Gets U.S. Approval; Shares Jump

By Ian Walker

 

Shares of Angle PLC rose 24% on Wednesday after the company said that the U.S. Food and Drug Administration has cleared its Parsortix system for patients with metastatic breast cancer.

Shares at 1139 GMT were up 24.0 pence at 122.50 pence.

The U.K. liquid-biopsy company's Parsortix system harvests cancer cells from blood for analysis.

"This ground-breaking, first-ever FDA product clearance in metastatic breast cancer provides the platform for Angle to work with our collaborators and customers to support further FDA submissions and the establishment of numerous specific clinical uses across different cancer types," Founder and Chief Executive Andrew Newland said.

 

Write to Ian Walker at ian.walker@wsj.com

 

(END) Dow Jones Newswires

May 25, 2022 08:05 ET (12:05 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.